Answers are grounded in this paper and cite their sources.
Synthesis evaluates antimicrobial activity in bacteria and fungi, suggesting potential treatment options.
The antimicrobial potential of synthesized derivatives A1–A5 and B1–B5 was evaluated against Gram-negative bacteria (P. aeruginosa, E. coli), Gram-positive bacteria (S. aureus, B. subtilis), and C. albicans using minimum inhibitory concentration (MIC, µg/mL) and zone of inhibition (ZOI, mm) assays. Among Gram-negative strains, B2 exhibited the best activity against P. aeruginosa (MIC 80 µg/mL; ZOI 12 mm), followed by B1 (MIC 160 µg/mL; ZOI 12 mm), whereas all compounds were inactive against E. coli (MIC ≥320 µg/mL; ZOI 10 mm). Significant Gram-positive activity was observed for A4 and A5 against S. aureus (MIC 10 µg/mL; ZOI 14–15 mm). A4 also showed potent activity against B. subtilis (MIC 10 µg/mL; ZOI 12 mm), while B3 demonstrated notable inhibition (MIC 320 µg/mL; ZOI 26 mm). In antifungal screening, A1 and B1 displayed promising activity against C. albicans (MIC 20 µg/mL; ZOI 15 and 22 mm, respectively). These findings indicate selective and moderate antimicrobial efficacy among the tested derivatives.
No takes yet. Share an insight, caveat, or question.
Chetankumar D. Bulsara1, Faiyazalam M. Shaikh1, Hetal I. Soni1, Vatsal M. Patel1*, Navin B. Patel2 (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: